



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

12th August, 2021

Corporate Relationship Department
M/s .BSE Ltd.
Dalal Street, Fort
Mumbai – 400 001.

The Manager – Listing
M/s.National Stock Exchange of India Ltd.
Exchange Plaza, Bandra-Kurla Complex
Bandra(E), **MUMBAI – 400 051.**

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Sub: Outcome of Board Meeting

We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business:

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June 2021 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time ("Listing Regulations") along with Limited Review Report of the Statutory Auditors. Please find enclosed a copy of the same.
2. Declared interim dividend of Rs.2/- (Rupees Two only) (100%) each per equity share of Rs.2/- (Rupees two only) each for the financial year 2021-22. The date for taking on record of its shareholders eligible for the purpose of payment of interim dividend i.e., record date is fixed as **Wednesday the 25th day of August, 2021.** The payment of said interim dividend will be paid from 31st August 2021.


We are also updating the financial results on the website of the Company.

Please find enclosed press release on Q1 FY 2021-22 results.

Meeting commenced at 10.45 a.m. and concluded at 1.00 p.m.

This is for your information.

Thanking you

Yours faithfully,
For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)

Encl: as above



NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034.
Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2021

(₹ in millions except per share data)

S.No.	Particulars	Quarter ended		Year ended	
		30 June 2021	31 March 2021	30 June 2020	31 March 2021
		Unaudited	Audited (Refer note 4)	Unaudited	Audited
	Income				
1	Revenue from operations	4,103	3,313	5,634	20,521
2	Other income	170	284	187	1,036
3	Total income (1+2)	4,273	3,597	5,821	21,557
	Expenses				
	Cost of materials consumed	1,099	893	1,214	3,729
	Purchases of stock-in-trade	77	30	432	1,866
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(385)	(378)	143	(481)
	Employee benefits expense	1,081	946	952	4,149
	Finance costs	20	35	37	133
	Depreciation and amortisation expense	338	304	280	1,169
	Other expenses	1,133	1,060	1,182	5,196
	Total expenses	3,363	2,890	4,240	15,761
5	Profit before exceptional items and tax (3-4)	910	707	1,581	5,796
6	Exceptional items	-	-	-	-
7	Profit before tax (5-6)	910	707	1,581	5,796
8	Tax expense				
	(i) Current tax	156	188	425	1,408
	(ii) Income-tax for earlier years	-	70	-	70
	(iii) Deferred tax charge /(credit)	4	(81)	(65)	(106)
	Total tax expense	160	177	360	1,372
9	Profit for the period/year (7-8)	750	530	1,221	4,424
10	Other comprehensive income (net of tax)				
	A. Items that will not be reclassified subsequently to profit or loss:				
	Remeasurement of defined benefit plans	(2)	51	(20)	(8)
	Net gains / (losses) from investments in equity instruments designated at Fair value through other comprehensive income (FVTOCI)	100	7	19	143
	Income-tax relating to items that will not be reclassified to profit or loss	(10)	3	(1)	(10)
		88	61	(2)	125
	B. Items that will be reclassified subsequently to profit or loss:				
	Exchange differences on translation of foreign operations	(20)	9	23	(38)
		(20)	9	23	(38)
	Total other comprehensive income (net of tax) (A+B)	68	70	21	87
11	Total comprehensive income for the period/ year (9+10)	818	600	1,242	4,511
12	Profit for the period/year attributable to:				
	Owners of the Company	750	530	1,228	4,409
	Non-controlling interests*	-	0	(7)	15
13	Other comprehensive income attributable to:				
	Owners of the Company	68	70	21	87
	Non-controlling interests	-	-	-	-
14	Total comprehensive income attributable to:				
	Owners of the Company	818	600	1,249	4,496
	Non-controlling interests*	-	0	(7)	15
15	Paid-up equity share capital (face value of ₹2 each)	365	365	364	365
16	Other equity				40,851
17	Earnings per share (face value ₹2 each)				
	Basic (in ₹)	4.11	2.91	6.74	24.20
	Diluted (in ₹)	4.11	2.90	6.73	24.16
		(Non-annualised)	(Non-annualised)	(Non-annualised)	

*The numbers are rounded off to nearest million.

See accompanying notes to the financial results.



NATCO Pharma Limited

Segment reporting:

(₹ in millions except share data)

S.No.	Particulars	Quarter ended			Year ended
		30-Jun-21	31 March 2021	30-Jun-20	31 March 2021
		Unaudited	Audited (refer note 4)	Unaudited	Audited
1	Segment revenue				
	a. Pharmaceuticals	4,097	3,300	5,634	20,500
	b. Agro chemicals	6	13	-	21
		4,103	3,313	5,634	20,521
	Add: Unallocated	-	-	-	-
	Total revenue from operations	4,103	3,313	5,634	20,521
2	Segment results				
	a. Pharmaceuticals	949	752	1,618	5,941
	b. Agro chemicals	(19)	(10)	-	(12)
	Total segment result	930	742	1,618	5,929
	Less:				
	a. Finance cost	(20)	(35)	(37)	(133)
	b. Net unallocated (income)/expenditure	-	-	-	-
	Total profit before tax	910	707	1,581	5,796
3	Segment assets				
	a. Pharmaceuticals	41,586	42,452	44,871	42,452
	b. Agro chemicals	3,008	2,393	1,610	2,393
	Total segment assets	44,594	44,845	46,481	44,845
	Add:				
	a. Unallocated	4,016	3,074	1,305	3,074
	Total assets	48,610	47,919	47,786	47,919
4	Segment liabilities				
	a. Pharmaceuticals	4,059	3,499	4,653	3,499
	b. Agro chemicals	178	84	83	84
	Total segment liabilities	4,237	3,583	4,736	3,583
	Add:				
	a. Unallocated	2,317	3,102	3,885	3,102
	Total liabilities	6,554	6,685	8,621	6,685





NATCO Pharma Limited

Notes to unaudited consolidated financial results:

- 1) The unaudited consolidated financial results of NATCO Pharma Limited ("the Company") and its subsidiaries (together referred as "the Group") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2) The unaudited consolidated financial results for the quarter ended 30 June 2021 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 12 August 2021.
- 3) The results of the Group for the quarter ended 30 June 2021, have been reviewed by the statutory auditors and they have issued an unqualified review report on the same. The review report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
- 4) The results of the quarter ended 31 March 2021 are balancing figures between audited consolidated figures in respect of the full financial year and the published unaudited year to date consolidated figures upto third quarter of the financial year. Also, the consolidated figures upto the end of third quarter were only reviewed and not subjected to audit.
- 5) The consolidated financial results for the quarter ended 30 June 2021 include financial results of the following subsidiaries:

Sr. No	Name of the Entity
1	NATCO Pharma Inc., United States of America
2	Time Cap Overseas Limited, Mauritius
3	NATCO Farma do Brasil Ltda, Brazil (subsidiary of Time Cap Overseas Limited)
4	NATCO Pharma (Canada) Inc., Canada
5	NATCO Pharma Asia Pte. Ltd., Singapore
6	NATCO Pharma Australia PTY Ltd., Australia
7	NATCO Lifesciences Philippines Inc., Philippines

- 6) The Group has considered internal and external sources of information while assessing the recoverability of its assets upto the date of approval of these financial results by the Board of Directors. Based on such assessment and considering the current economic indicators, the Group expects to recover the carrying amount of these assets. The Board of Directors has also considered the impact of COVID-19 on the business for the foreseeable future and have concluded that the Group has sufficient resources to continue as a going concern. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes to future economic conditions.
- 7) The unaudited standalone financial results, for the quarter ended 30 June 2021 can be viewed on the website of the Company, NSE and BSE at www.natcopharma.co.in, www.nseindia.com, and www.bseindia.com respectively. Information of audited standalone financial results of the Company in terms of Regulation 47(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as under:

(₹ in millions)

Particulars	Quarter ended			Year ended	
	30 June 2021	31 March 2021	30 June 2020	31 March 2021	
	Unaudited	Audited	Unaudited	Audited	
Total revenue from operations	3,938	3,115	5,322	16,535	
Profit before tax	910	734	1,616	3,922	
Net profit for the period/ year	752	572	1,267	3,095	
Total comprehensive income	839	635	1,272	3,228	

- 8) The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Group will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.
- 9) The Board of Directors in their meeting held on 12 August 2021 have recommended an interim dividend of ₹ 2 per equity share of ₹ 2 each for the quarter ended 30 June 2021.
- 10) Figures for the previous periods/ year have been regrouped, wherever necessary, to correspond with the figures of the current period.

By order of the Board For NATCO Pharma Limited



V C Nannapaneni

V C Nannapaneni
Chairman and Managing Director
(DIN: 00183315)

Place: Hyderabad
Date: 12 August 2021

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City
Orwell, B Wing, 6th Floor, Unit - 3
Sy No. 83/1, Plot No. 2, Raidurg
Hyderabad - 500 081, India.

Telephone +91 40 7182 2000
Fax +91 40 7182 2399

Limited review report on unaudited quarterly consolidated financial results of NATCO Pharma Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations')

To
The Board of Directors of NATCO Pharma Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of NATCO Pharma Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended 30 June 2021 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the entity	Relationship
NATCO Pharma Limited	Parent
NATCO Pharma, Inc.	Subsidiary
Time Cap Overseas Limited	Subsidiary
NATCO Farma Do Brasil Ltda. (subsidiary of Time Cap Overseas Limited)	Step-down subsidiary
NATCO Pharma (Canada) Inc.	Subsidiary
NATCO Pharma Asia Pte. Ltd.	Subsidiary
NATCO Pharma Australia PTY Ltd.	Subsidiary
NATCO Lifesciences Philippines Inc.	Subsidiary

B S R & Associates LLP

Limited review report on unaudited quarterly consolidated financial results of NATCO Pharma Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations') (continued)

5. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the interim financial information of seven subsidiaries included in the Statement, whose interim financial information reflect (before consolidation adjustments) total revenues of INR 393.04 million, total net profit after tax of INR 0.36 million and total comprehensive income of INR 1.21 million for the quarter ended 30 June 2021, as considered in the consolidated unaudited financial results. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

These subsidiaries are located outside India whose interim financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's Management has converted the financial information of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Parent's Management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the reports of other auditors and the conversion adjustments prepared by the Management of the Parent and reviewed by us.

Our conclusion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

for **B S R & Associates LLP**

Chartered Accountants

ICAI Firm Registration No. 116231W/ W-100024

VIKASH Digitally signed by
VIKASH SOMANI
SOMANI Date: 2021.08.12
12:31:24 +05'30'

Vikash Somani

Partner

Membership Number: 061272

UDIN: 21061272AAAACG9500

Place: Hyderabad

Date: 12 August 2021



NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034
Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2021

(₹ in millions except share data)

S.No.	Particulars	Quarter ended			Year ended
		30 June 2021	31 March 2021	30 June 2020	31 March 2021
		Unaudited	Audited (Refer note 4)	Unaudited	Audited
	Income				
1	Revenue from operations	3,938	3,115	5,322	16,535
2	Other income	123	291	199	1,011
3	Total income (1+2)	4,061	3,406	5,521	17,546
	Expenses				
	Cost of materials consumed	1,099	893	1,214	3,729
	Purchases of stock-in-trade	58	19	433	1,740
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(352)	(364)	97	(469)
	Employee benefits expense	971	894	900	3,800
	Finance costs	18	23	33	113
	Depreciation and amortisation expense	331	298	276	1,152
	Other expenses	1,026	909	952	3,559
	Total expenses	3,151	2,672	3,905	13,624
5	Profit before exceptional items and tax (3-4)	910	734	1,616	3,922
6	Exceptional items	-	-	-	-
7	Profit before tax (5-6)	910	734	1,616	3,922
	Tax expense				
	(i) Current tax	155	173	414	863
	(ii) Income-tax for earlier years	-	70	-	70
	(ii) Deferred tax charge /(credit)	3	(81)	(65)	(106)
	Total tax expense	158	162	349	827
9	Profit for the period/ year (7-8)	752	572	1,267	3,095
	Other comprehensive income (net of tax)				
	Items that will not be reclassified to profit or loss:				
	Remeasurement of defined benefit plans	(2)	51	(20)	(8)
	Net gains / (losses) from investments in equity instruments designated at FVTOCI	100	9	28	153
	Income-tax relating to items that will not be reclassified to profit or loss	(11)	3	(3)	(12)
	Total other comprehensive income (net of tax)	87	63	5	133
11	Total comprehensive income for the period/ year (9+10)	839	635	1,272	3,228
12	Paid-up equity share capital (face value of ₹2 each)	365	365	364	365
13	Other equity				40,546
	Earnings per share (face value ₹2 each)				
	Basic (in ₹)	4.12	3.14	6.96	16.99
	Diluted (in ₹)	4.12	3.13	6.94	16.96
		(Non-annualised)	(Non-annualised)	(Non-annualised)	

See accompanying notes to the financial results.




NATCO Pharma Limited

Notes to the unaudited standalone financial results:

- 1) The standalone financial results of NATCO Pharma Limited ("the Company") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2) The standalone financial results for the quarter ended 30 June 2021 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 12 August 2021.
- 3) The results of the Company for the quarter ended 30 June 2021, have been reviewed by the statutory auditors and they have issued an unqualified review report on the same. The review report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
- 4) The figures for the quarter ended 31 March 2021 as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures upto the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
- 5) Where financial results contain both consolidated and standalone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly, segment information has been presented in the consolidated financial results.
- 6) The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.
- 7) The Company has considered internal and external sources of information while assessing the recoverability of its assets upto the date of approval of these financial results by the Board of Directors. Based on such assessment and considering the current economic indicators, the Company expects to recover the carrying amount of these assets. The Board of Directors has also considered the impact of COVID-19 on the business for the foreseeable future and have concluded that the Company has sufficient resources to continue as a going concern. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes to future economic conditions.
- 8) The Board of Directors at their meeting held on 12 August 2021 have recommended an interim dividend of ₹2 per equity share of ₹2 each for the quarter ended 30 June 2021.
- 9) Figures for the previous periods/ year have been regrouped, wherever necessary, to correspond with the figures of the current period.

**By order of the Board
For NATCO Pharma Limited**




V C Nannapaneni
Chairman and Managing Director
(DIN: 00183315)

Place: Hyderabad
Date: 12 August 2021

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City
Orwell, B Wing, 6th Floor, Unit - 3
Sy No. 83/1, Plot No. 2, Raidurg
Hyderabad - 500 081, India.

Telephone +91 40 7182 2000
Fax +91 40 7182 2399

Limited review report on unaudited quarterly standalone financial results of NATCO Pharma Limited ('the Company') pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

To
The Board of Directors of NATCO Pharma Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of NATCO Pharma Limited for the quarter ended 30 June 2021 ("the Statement").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

B S R & Associates LLP

Limited review report on unaudited quarterly standalone financial results of NATCO Pharma Limited ('the Company') pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') (continued)

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **B S R & Associates LLP**

Chartered Accountants

ICAI Firm Registration number: 116231W/W-100024

VIKASH
SOMANI

Digitally signed
by VIKASH
SOMANI
Date: 2021.08.12
12:32:17 +05'30'

Vikash Somani

Partner

Membership No: 061272

UDIN No.: 21061272AAAACF5732

Place: Hyderabad

Date: 12 August 2021



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/12/2021-22

Press Release

Hyderabad, 12th August 2021

NATCO records INR 427.30 Crore consolidated revenue and INR 75 Crore of profit, after tax, for the first quarter ended 30th June 2021

Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of INR 427.30 Crore for the quarter ended on 30th June 2021 as against INR 582.10 crores for Q 1, FY 2020. The net profit after tax for the period, on a consolidated basis, was INR 75 Crore as against INR 122.10 crores for same quarter in the last financial year.

The degrowth in sales can be partially attributed to the higher proportion of initial phase of pandemic exports to USA in Chloroquine Phosphate tablets and Oseltamivir Phosphate capsules in the revenues for the quarter ended 30th June 2020.

The pandemic continues to impact the revenues of the company but recovered compared to quarter ending March 2021.

The Company has strong product launches both in Export markets and domestic India business during the current financial year and expects to have good growth.

Segmental Revenue Split (All Figures in INR Crore)-

Segment	Revenue in INR Crores Q1 FY22
API	61.6
Formulations, Domestic	200.6
Formulations, Exports (incl. Profit Share & Foreign Subs)	145.4
Other Operating income & non-operating income	19.2
Crop Health Sciences (CHS)	0.5

The Board of Directors has recommended an interim dividend of INR 2.0 per equity share of INR 2.0 each, during the First Quarter of FY2021-22.

Forwarded for favour of publication

For NATCO Pharma Limited

M Adinarayana

M Adinarayana

Company Secretary &

Vice President (Legal & Corp. Affairs)